Get the Stockscreener App
1.13
0.88%
-0.01
After Hours:
1.13
Repare Therapeutics Inc stock is traded at $1.13, with a volume of 77,832.
It is down -0.88% in the last 24 hours and down -14.39% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
See More
Previous Close:
$1.14
Open:
$1.13
24h Volume:
77,832
Relative Volume:
0.17
Market Cap:
$48.46M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-0.5067
EPS:
-2.23
Net Cash Flow:
$-129.10M
1W Performance:
+0.00%
1M Performance:
-14.39%
6M Performance:
-67.71%
1Y Performance:
-78.44%
1-Day Range:
$1.12
$1.16
1-Week Range:
$1.08
$1.17
52-Week Range:
$1.06
$5.52
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.13 | 48.46M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Fierce Biotech Layoff Tracker 2025: Cargo lays off 90% of staff; Empress halves workforce - Fierce Biotech
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - Benzinga
Repare therapeutics’ chief scientific officer sells $6,396 in shares - Investing.com India
Repare therapeutics’ chief medical officer sells shares for $4,099 By Investing.com - Investing.com South Africa
Repare therapeutics CEO Segal Lloyd Mitchell sells $24,144 in shares By Investing.com - Investing.com South Africa
Repare therapeutics CEO Segal Lloyd Mitchell sells $24,144 in shares - Investing.com
Repare therapeutics’ chief scientific officer sells $6,396 in shares By Investing.com - Investing.com Canada
Repare Therapeutics CEO Sells Shares to Cover Tax Obligations - TradingView
Layoff Tracker: GRO Biosciences Cuts Staff Amid Quest for Strategic Alternatives - BioSpace
HC Wainwright Issues Pessimistic Forecast for Repare Therapeutics (NASDAQ:RPTX) Stock Price - MarketBeat
What Makes Repare Therapeutics (RPTX) a New Buy Stock - Yahoo Finance
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
New Hires at Repare Get Stock Options as Share Price Shows 67% Drop - StockTitan
Repare Therapeutics stock target cut to $5 at H.C. Wainwright - Investing.com India
Repare Therapeutics stock target cut to $5 at H.C. Wainwright By Investing.com - Investing.com Canada
Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare Therapeutics - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Repare Therapeutics (NASDAQ:RPTX) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation - Yahoo Finance
Repare Therapeutics Focuses on Clinical Trials Amid Restructuring - TipRanks
Repare Therapeutics Restructures and Focuses on Key Clinical Trials - MSN
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results - CRISPR Medicine News
Repare Therapeutics anticipates key trial results by late 2025 - Investing.com Canada
Repare Therapeutics Inc. SEC 10-K Report - TradingView
Repare Therapeutics reports Q4 EPS (67c), consensus (79c) - TipRanks
Can Repare Therapeutics' Massive 75% Staff Cut Save Its Clinical Pipeline? - StockTitan
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Sold by ARK Investment Management LLC - MarketBeat
Repare Therapeutics stock hits 52-week low at $1.06 By Investing.com - Investing.com South Africa
Repare Therapeutics stock hits 52-week low at $1.06 - Investing.com
Repare Therapeutics cuts 75% of workforce - MSN
Repare Therapeutics to cut 75% of workforce in major restructuring - The Pharma Letter
Parp Inhibitor Market Future Business Opportunities 2025-2032 - openPR
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repare Therapeutics Inc Stock (RPTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 12 '25 |
Sale |
1.14 |
5,611 |
6,397 |
80,297 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 12 '25 |
Sale |
1.14 |
6,884 |
7,848 |
54,786 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Mar 12 '25 |
Sale |
1.14 |
21,179 |
24,144 |
124,394 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Mar 28 '24 |
Sale |
4.62 |
2,650 |
12,243 |
110,049 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Apr 01 '24 |
Sale |
4.63 |
2,491 |
11,533 |
107,558 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Sale |
4.62 |
825 |
3,812 |
45,564 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Apr 01 '24 |
Sale |
4.61 |
789 |
3,637 |
44,775 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 28 '24 |
Sale |
4.64 |
450 |
2,088 |
72,318 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Apr 01 '24 |
Sale |
4.66 |
410 |
1,911 |
71,908 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER |
Mar 28 '24 |
Sale |
4.64 |
500 |
2,320 |
231,709 |
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):